Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology
Publish Date: 2026-02-03 09:10:00
Source Domain: investingnews.com
(TheNewswire)
Key Highlights
-
Positive First-in-Human Results: Three-month Group 1 data met or exceeded expectations for safety, lens delivery, and vision performance.
-
Major De-Risking Milestone: The study successfully validated the core technology and cleared the path to the next clinical phase.
-
Life-Changing Vision Improvements: Patients with severe vision loss experienced meaningful improvements in everyday vision.
-
Strong Forward Momentum: Planning for Group 2 surgeries is underway, with lens and delivery enhancements already in development.
-
High Confidence Going Forward: Management remains fully confident in the Ocumetics accommodating intraocular lens platform following these results.
Calgary, Alberta – February 3, 2026 – TheNewswire – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC,OTC:OTCFF) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced positive three-month postoperative results from Group 1 patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”). The results validate the Company’s core technology and represent a key clinical de-risking milestone as Ocumetics advances toward subsequent study phases.
The Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance – successfully achieving the primary objectives required to progress the clinical program.
“These first-in-human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery, and strong visual outcomes,” said Dean Burns, President and CEO of Ocumetics. “Following a detailed review of the data with Dr. Raphael Vasquez, our primary surgeon, I remain 100% confident in our accommodating intraocular lens technology. Based on this success, we have initiated planning for Group 2 surgeries.”
…
